Literature DB >> 29363784

Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience.

Natalie C Ward1,2, Jing Pang1,3, Jacqueline D M Ryan1,4, Gerald F Watts1,3.   

Abstract

There is considerable evidence for the role of low-density lipoprotein cholesterol (LDL-C) in the development of atherosclerotic cardiovascular disease. Although statin therapy remains the most frequency prescribed medication to reduce LDL-C and lower risk of cardiovascular disease, a considerable number of patients develop muscle-related side affects. This review summarizes recent literature supporting the role of nutraceuticals as LDL-C-lowering therapy in statin-intolerant patients, with evidence from our own clinical practices.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Low-Density Lipoprotein Cholesterol; Nutraceuticals; SAMS; Statin Myopathy

Mesh：

Substances：

Year:  2018        PMID： 29363784      PMCID： PMC6489823          DOI： 10.1002/clc.22862

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN： 0160-9289            Impact factor:   2.882


  42 in total

Review 1.  The relationship of vitamin D deficiency to statin myopathy.

Authors:  Ankur Gupta; Paul D Thompson
Journal:  Atherosclerosis       Date:  2010-12-05       Impact factor: 5.162

2.  Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update.

Authors:  G B John Mancini; A Yashar Tashakkor; Steven Baker; Jean Bergeron; David Fitchett; Jiri Frohlich; Jacques Genest; Milan Gupta; Robert A Hegele; Dominic S Ng; Glen J Pearson; Janet Pope
Journal:  Can J Cardiol       Date:  2013-09-29       Impact factor: 5.223

3.  Lipid-lowering efficacy of red yeast rice in a population intolerant to statins.

Authors:  Carmelo V Venero; Jose V Venero; Dale C Wortham; Paul D Thompson
Journal:  Am J Cardiol       Date:  2010-03-01       Impact factor: 2.778

Review 4.  Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease.

Authors:  Helena Gylling; Jogchum Plat; Stephen Turley; Henry N Ginsberg; Lars Ellegård; Wendy Jessup; Peter J Jones; Dieter Lütjohann; Winfried Maerz; Luis Masana; Günther Silbernagel; Bart Staels; Jan Borén; Alberico L Catapano; Guy De Backer; John Deanfield; Olivier S Descamps; Petri T Kovanen; Gabriele Riccardi; Lale Tokgözoglu; M John Chapman
Journal:  Atherosclerosis       Date:  2013-11-23       Impact factor: 5.162

5.  Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.

Authors:  F Affuso; A Ruvolo; F Micillo; L Saccà; S Fazio
Journal:  Nutr Metab Cardiovasc Dis       Date:  2009-08-20       Impact factor: 4.222

Review 6.  The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials.

Authors:  Hui Dong; Yan Zhao; Li Zhao; Fuer Lu
Journal:  Planta Med       Date:  2013-03-19       Impact factor: 3.352

7.  Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial.

Authors:  David J Becker; Ram Y Gordon; Steven C Halbert; Benjamin French; Patti B Morris; Daniel J Rader
Journal:  Ann Intern Med       Date:  2009-06-16       Impact factor: 25.391

8.  Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.

Authors:  Steven C Halbert; Benjamin French; Ram Y Gordon; John T Farrar; Kathryn Schmitz; Patti B Morris; Paul D Thompson; Daniel J Rader; David J Becker
Journal:  Am J Cardiol       Date:  2009-11-26       Impact factor: 2.778

9.  Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment.

Authors:  Livia Pisciotta; Antonella Bellocchio; Stefano Bertolini
Journal:  Lipids Health Dis       Date:  2012-09-22       Impact factor: 3.876

10.  Treating statin-intolerant patients.

Authors:  Marcello Arca; Giovanni Pigna
Journal:  Diabetes Metab Syndr Obes       Date:  2011-04-28       Impact factor: 3.168
View more
  6 in total

Review 1.  Macroalgal Proteins: A Review.

Authors:  Ronan O' Brien; Maria Hayes; Gary Sheldrake; Brijesh Tiwari; Pamela Walsh
Journal:  Foods       Date:  2022-02-16

2.  Nutraceutical approach for the management of cardiovascular risk - a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study.

Authors:  Massimiliano Ruscica; Chiara Pavanello; Sara Gandini; Chiara Macchi; Margherita Botta; Daria Dall'Orto; Marina Del Puppo; Marco Bertolotti; Raffaella Bosisio; Giuliana Mombelli; Cesare R Sirtori; Laura Calabresi; Paolo Magni
Journal:  Nutr J       Date:  2019-02-22       Impact factor: 3.271

3.  Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia.

Authors:  Adrian M Di Bisceglie; Gerald F Watts; Philip Lavin; Meng Yu; Ru Bai; Liping Liu
Journal:  Lipids Health Dis       Date:  2020-11-12       Impact factor: 3.876

4.  Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (Bifidobacterium longum BB536, Red Yeast Rice Extract) (Randomized, Double-Blind, Placebo-Controlled Study).

Authors:  Stefania Cicolari; Chiara Pavanello; Elena Olmastroni; Marina Del Puppo; Marco Bertolotti; Giuliana Mombelli; Alberico L Catapano; Laura Calabresi; Paolo Magni
Journal:  Nutrients       Date:  2021-01-28       Impact factor: 5.717

5.  A Combination of Lactoplantibacillus plantarum Strains CECT7527, CECT7528, and CECT7529 Plus Monacolin K Reduces Blood Cholesterol: Results from a Randomized, Double-Blind, Placebo-Controlled Study.

Authors:  Rafael Guerrero-Bonmatty; Guadalupe Gil-Fernández; Francisco José Rodríguez-Velasco; Jordi Espadaler-Mazo
Journal:  Nutrients       Date:  2021-04-06       Impact factor: 5.717

6.  Atorvastatin Ester Regulates Lipid Metabolism in Hyperlipidemia Rats via the PPAR-signaling Pathway and HMGCR Expression in the Liver.

Authors:  Nan Hu; Chunyun Chen; Jinhui Wang; Jian Huang; Dahong Yao; Chunli Li
Journal:  Int J Mol Sci       Date:  2021-10-14       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.